{"product_id":"global-point-of-care-testing-poct-market-by-diagnostics-segment-mode-platform-end-users-region-trends-recent-developments-company-profiles-forecast-to-2030","title":"Global Point of Care Testing (POCT) Market (By Diagnostics Segment, Mode, Platform, End Users, Region), Trends, Recent Developments, Company Profiles - Forecast to 2030","description":"\u003cp\u003eGlobal Point of Care Testing (POCT) Market (By Diagnostics Segment, Mode, Platform, End Users, Region), Trends, Recent Developments, Company Profiles - Forecast to 2030\u003cbr\u003e\nThe global point of care testing (POCT) market is predicted to surpass US$ 75.2 Billion by 2030. POCT or near-patient testing is a medical diagnostic test that allows physicians and medical staff to correctly attain real-time, lab-quality diagnostic results within minutes rather than hours. POCT has skyrocketed in the last 20 years, backed by the increasing introduction of transportable, portable, and handheld instruments that has resulted in the migration of POC testing from the hospital environment to a range of medical environments including the workplace, home, disaster care and most recently, convenience clinics.\u003c\/p\u003e \n\n\u003cp\u003eThe demand for accurate and fast testing has blossomed both inside and outside the hospital setting. The rising incidence of infectious diseases and chronic conditions such as cardiovascular diseases and diabetes in developing countries such as India and China have stimulated demand for point of care testing services. As per statistics of the International Diabetes Federation, in 2021, approximately 537 million adults (20-79 years) are living with diabetes globally, and it is estimated to reach 643 million by 2030 and 783 million by 2045. Hence, the growing infectious diseases and chronic conditions will drive the point of care testing market over the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eBy Diagnostics Segment: Global Point of Care Testing Market \u0026amp; Forecast – Key Takeaways\u003c\/p\u003e\n\n\u003cp\u003eBased on diagnostics segment, the point of care testing market is dominated by blood glucose testing segment. Increasing prevalence of diabetes and the rising inclination of patients towards home testing is the major driver that will drive segmental growth over the forecast timeframe. \u003cbr\u003e\nThe infectious diseases segment held second largest revenue share in 2022. Infectious diseases are the primary cause of mortality globally, and according to figures from the Clinical Microbiology and Infection journal, they claim over 14 million lives annually, making up around 25% of the 56 million deaths recorded worldwide. \u003cbr\u003e\nCardiac marker segment is expected to grow at a significant rate over the forecast period. The growing prevalence of cardiovascular ailments, increasing purchasing power, rise in the geriatric population, associated with high susceptibility to chronic diseases related to cardiac disorders, and economical diagnosis of chronic diseases in rural areas is expected to drive the market for cardiac markers.\u003c\/p\u003e \n\n\u003cp\u003eBy Mode: Global Point of Care Testing Market \u0026amp; Forecast – Key Takeaways\u003c\/p\u003e\n\n\u003cp\u003eOn the basis of mode, the point of care testing market is dominated by OTC-based testing segment, as these tests are cost-effective as well as easy operative in nature. These tests do not require skilled professional to perform and can be self-tested by individuals, thereby boosting the market growth. \u003cbr\u003e\nThe Prescription based testing segment is expected to grow at the highest rate over the forecast period.\u003c\/p\u003e \n\n\u003cp\u003eBy Platform: Global Point of Care Testing Market \u0026amp; Forecast – Key Takeaways\u003c\/p\u003e\n\n\u003cp\u003eBy platform, the Lateral Flow Assays (LFA) segment accounted for largest revenue share in 2022. POC tests based on lateral flow assays are increasingly being employed to replace long, conventional laboratory processes. \u003cbr\u003e\nThe point of care testing market for immunoassays technology is expected to witness significant growth over the forecast timeframe. Rapid immunoassays improve quality of care through its performance at point of care facilities, such as student health clinics, labor and delivery suites and emergency rooms. The cost-effectiveness offered by these immunoassays will influence segment growth over the forecast period. \u003cbr\u003e\nMicrofluidic based point-of-care testing provides prompt results and also improves disease detection and diagnosis with the help of small sample volumes.\u003c\/p\u003e \n\n\u003cp\u003eBy End Users: Global Point of Care Testing Market \u0026amp; Forecast – Key Takeaways\u003c\/p\u003e\n\n\u003cp\u003eBased on end users, the point of care testing market is segmented into Hospitals, Clinics, Laboratories, Home Care and Assisted Living Healthcare Facilities. \u003cbr\u003e\nHospitals held majority of the point of care testing market, followed by Clinics. Increase in prevalence of chronic conditions such as cancer and cardiovascular diseases that require proper monitoring and prefer minimally invasive procedures are carried out in hospitals and clinics. \u003cbr\u003e\nThe home care segment is expected to grow at the highest rate over the forecast period driven by increasing preference for home and remote monitoring and rising demand for rapid tests among home care users.\u003c\/p\u003e\n\n\u003cp\u003eBy Region: Global Point of Care Testing Market \u0026amp; Forecast – Key Takeaways\u003c\/p\u003e\n\n\u003cp\u003eThe point of care testing market, by region, is dominated by North America and is expected to maintain its position throughout the forecast period. This can be attributed to rising prevalence of chronic disorders and infectious diseases, which need portable and rapid diagnosis, increasing number of product approvals, and rising government initiatives to support the adoption of POCT in this region. \u003cbr\u003e\nEurope held second highest share of the point of care testing market. \u003cbr\u003e\nAsia-Pacific point of care testing market is expected to grow at the fastest rate over the forecast period driven by growing geriatric population base, rising prevalence of target diseases, increasing demand for home healthcare and the introduction of new products enabled with advanced technologies.\u003c\/p\u003e\n\n\u003cp\u003eiGATE RESEARCH report titled “Global Point of Care Testing (POCT) Market (By Diagnostics Segment, Mode, Platform, End Users, Region), Trends, Recent Developments, Company Profiles - Forecast to 2030” provides a comprehensive analysis of the Global Point of Care Testing Market.\u003c\/p\u003e\n\n\u003cp\u003eThis 303 Page report with 78 Figures and 12 Tables has been analyzed from 10 View Points:\u003c\/p\u003e\n\n\u003cp\u003e1) Global - Point of Care Testing Market \u0026amp; Forecast (2012 - 2030)\u003cbr\u003e\n2) Global - Point of Care Testing Market Share and Forecast (2012 - 2030)\u003cbr\u003e\n3) By Diagnostics Segment - Global Point of Care Testing Market \u0026amp; Forecast (2012 - 2030)\u003cbr\u003e\n4) By Mode - Global Point of Care Testing Market \u0026amp; Forecast (2012 - 2030) \u003cbr\u003e\n5) By Platform - Global Point of Care Testing Market \u0026amp; Forecast (2015 - 2030)\u003cbr\u003e\n6) By End Users - Global Point of Care Testing Market \u0026amp; Forecast (2012 - 2030)\u003cbr\u003e\n7) By Region - Global Point of Care Testing Market \u0026amp; Forecast (2012 - 2030)\u003cbr\u003e\n8) Global Point of Care Testing Market - Recent Developments\u003cbr\u003e\n9) Global Point of Care Testing Market - 106 Company Profiles \u003cbr\u003e\n10) Global Point of Care Testing Market - Growth Drivers \u0026amp; Challenges\u003c\/p\u003e\n\n\u003cp\u003eBy Diagnostics Segment - Global Point of Care Testing Market \u0026amp; Forecast\u003c\/p\u003e \n\n\u003cp\u003e1. Blood Glucose Testing\u003cbr\u003e\n2. Cardiac Marker Testing\u003cbr\u003e\n3. Lipid Panel\/Cholesterol Testing\u003cbr\u003e\n4. Coagulation Testing\u003cbr\u003e\n5. Infectious Disease Testing\u003cbr\u003e\n6. Urinalysis Testing\u003cbr\u003e\n7. Drug of Abuse Testing\u003cbr\u003e\n8. Fecal Occult Blood Testing\u003cbr\u003e\n9. Pregnancy \u0026amp; Fertility Testing\u003cbr\u003e\n10. Tumor Marker Testing\u003cbr\u003e\n11. Critical Care Testing\u003cbr\u003e\n12. HbA1c Testing \u003cbr\u003e\n13. Clinical Chemistry Testing\u003cbr\u003e\n14. Bilirubin Testing\u003cbr\u003e\n15. Hematology Testing\u003c\/p\u003e\n\n\u003cp\u003eBy Mode - Global Point of Care Testing Market \u0026amp; Forecast\u003c\/p\u003e \n\n\u003cp\u003ePrescription-based Testing \u003cbr\u003e\nOTC-based Testing\u003c\/p\u003e\n\n\u003cp\u003eBy Platform - Global Point of Care Testing Market \u0026amp; Forecast\u003c\/p\u003e \n\n\u003cp\u003eLateral Flow Assays\u003cbr\u003e\nImmunoassays\u003cbr\u003e\nMicrofluidics\u003cbr\u003e\nDipsticks\u003cbr\u003e\nMolecular Diagnostics\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy End Users - Global Point of Care Testing Market \u0026amp; Forecast\u003c\/p\u003e\n\n\u003cp\u003e1. Hospitals\u003cbr\u003e\n2. Clinics\u003cbr\u003e\n3. Laboratories\u003cbr\u003e\n4. Assisted Living Healthcare Facilities\u003cbr\u003e\n5. Home Care\u003c\/p\u003e\n\n\u003cp\u003eBy Region - Global Point of Care Testing Market \u0026amp; Forecast\u003c\/p\u003e\n\n\u003cp\u003e1. North America\u003cbr\u003e\n2. Europe\u003cbr\u003e\n3. Asia Pacific\u003cbr\u003e\n4. Latin America\u003cbr\u003e\n5. Middle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eGlobal Point of Care Testing Market - 106 Company Profiles\u003c\/p\u003e\n\n\u003cp\u003e1. Abbott Laboratories\u003cbr\u003e\n2. Siemens Healthineers\u003cbr\u003e\n3. Roche Diagnostics\u003cbr\u003e\n4. Quest Diagnostics\u003cbr\u003e\n5. Becton, Dickinson and Company\u003cbr\u003e\n6. ACON Laboratories\u003cbr\u003e\n7. Abaxis, Inc\u003cbr\u003e\n8. Abingdon Health, Ltd\u003cbr\u003e\n9. Access Bio, Inc.\u003cbr\u003e\n10. AccuBioTech Co, Ltd.\u003cbr\u003e\n11. Akers Biosciences, Inc.\u003cbr\u003e\n12. Alfa Scientific Designs, Inc\u003cbr\u003e\n13. American Bio Medica Corporation\u003cbr\u003e\n14. AmniSure International\u003cbr\u003e\n15. Aquila Diagnostic Systems, Inc\u003cbr\u003e\n16. ARKRAY Inc\u003cbr\u003e\n17. Artron Laboratories Inc.\u003cbr\u003e\n18. Ascensia Diabetes Care Holdings AG\u003cbr\u003e\n19. Immune IQ (Formerly Ativa) 20. Atlas Link Biotech Co., Ltd\u003cbr\u003e\n21. Audit Diagnostics\u003cbr\u003e\n22. Augurix Diagnostics\u003cbr\u003e\n23. Autobio Diagnostics Co., Ltd\u003cbr\u003e\n24. Axxin\u003cbr\u003e\n25. Beckman Coulter, Inc\u003cbr\u003e\n26. Bhat Bio-Tech India Private Ltd.\u003cbr\u003e\n27. bioLytical Laboratories\u003cbr\u003e\n28. BioMedomics, Inc\u003cbr\u003e\n29. Biomerica, Inc.\u003cbr\u003e\n30. bioMerieux SA\u003cbr\u003e\n31. Biophor Diagnostics, Inc\u003cbr\u003e\n32. Bio-Rad Laboratories Inc.\u003cbr\u003e\n33. Bioscan Screening Systems, Inc.\u003cbr\u003e\n34. Biosensia Ltd.\u003cbr\u003e\n35. BTNX Inc.\u003cbr\u003e\n36. Boditech Med Inc\u003cbr\u003e\n37. Xiamen Boson Biotech Co. Ltd\u003cbr\u003e\n38. Calypte Biomedical Corporation 39. Cepheid, Inc\u003cbr\u003e\n40. Chembio Diagnostic Systems, Inc\u003cbr\u003e\n41. Clarity Diagnostics, LLC\u003cbr\u003e\n42. Confirm Biosciences\u003cbr\u003e\n43. CTK Biotech, Inc.\u003cbr\u003e\n44. Daktari Diagnostics\u003cbr\u003e\n45. Danaher Corporation\u003cbr\u003e\n46. Dexcom, Inc\u003cbr\u003e\n47. DIALAB GmbH\u003cbr\u003e\n48. DiaSys Diagnostic Systems GmbH\u003cbr\u003e\n49. Diazyme Laboratories, Inc.\u003cbr\u003e\n50. DNA Electronics Ltd. (DNAe)\u003cbr\u003e\n51. EKF Diagnostics Holdings plc\u003cbr\u003e\n52. ELITechGroup, Inc.\u003cbr\u003e\n53. Eurolyser Diagnostica GmbH\u003cbr\u003e\n54. Exact Sciences Corporation 55. Exalenz Bioscience Ltd\u003cbr\u003e\n56. Genedrive plc\u003cbr\u003e\n57. GeTein BioMedical, Inc.\u003cbr\u003e\n58. Helena Laboratories\u003cbr\u003e\n59. Hemosure, Inc.\u003cbr\u003e\n60. Immunostics, Inc.\u003cbr\u003e\n61. Instrumentation Laboratory \u003cbr\u003e\n62. JAL Innovation PTE LTD \u003cbr\u003e\n63. Jant Pharmacal Corporation \u003cbr\u003e\n64. LamdaGen Corporation \u003cbr\u003e\n65. LifeScan, Inc\u003cbr\u003e\n66. LifeSign, LLC\u003cbr\u003e\n67. MBio Diagnostics, Inc (Now LightDeck Diagnostics) \u003cbr\u003e\n68. Medix Biochemica\u003cbr\u003e\n69. Medtronic, Inc\u003cbr\u003e\n70. A. Menarini Diagnostics S.R.L.\u003cbr\u003e\n71. Meridian Bioscience, Inc\u003cbr\u003e\n72. Nano-Ditech Corporation\u003cbr\u003e\n73. Noble Medical, Inc\u003cbr\u003e\n74. Nova Biomedical, Corp.\u003cbr\u003e\n75. Oasis Diagnostics Corporation\u003cbr\u003e\n76. OPKO Health, Inc\u003cbr\u003e\n77. OPTI Medical Systems, Inc\u003cbr\u003e\n78. OraSure Technologies, Inc\u003cbr\u003e\n79. Polymed Therapeutics Inc.\u003cbr\u003e\n80. Preventis GmbH\u003cbr\u003e\n81. Princeton Biomeditech Corporation\u003cbr\u003e\n82. QuantuMDx Group Limited\u003cbr\u003e\n83. Radiometer Medical A\/S\u003cbr\u003e\n84. Response Biomedical Corp\u003cbr\u003e\n85. Reszon Diagnostics International Sdn. Bhd.\u003cbr\u003e\n86. Samsung Healthcare\u003cbr\u003e\n87. Savyon Diagnostics\u003cbr\u003e\n88. Sekisui Diagnostics LLC\u003cbr\u003e\n89. Siloam Biosciences, Inc \u003cbr\u003e\n90. Sysmex Corporation\u003cbr\u003e\n91. TECHLAB, Inc.\u003cbr\u003e\n92. Teco Diagnostics\u003cbr\u003e\n93. Trinity Biotech PLC \u003cbr\u003e\n94. Trividia Health\u003cbr\u003e\n95. Tulip Diagnostics Ltd\u003cbr\u003e\n96. Veredus Laboratories PTE Ltd\u003cbr\u003e\n97. Vircell\u003cbr\u003e\n98. WAMA Diagnostica\u003cbr\u003e\n99. Wave \u003cbr\u003e\n80 Biosciences\u003cbr\u003e\n100. Werfen \u003cbr\u003e\n101. Quidel Corporation \u003cbr\u003e\n102. Thermo Fisher Scientific \u003cbr\u003e\n103. Mesa Biotech Inc \u003cbr\u003e\n104. GeneSTAT Molecular Diagnostics, LLC\u003cbr\u003e\n105. Biocartis Group NV\u003cbr\u003e\n106. Johnson and Johnson Services, Inc.\u003c\/p\u003e \n\n\u003cp\u003eData Source\u003c\/p\u003e\n\n\u003cp\u003eiGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.\u003c\/p\u003e\n\n\u003cp\u003eResearch Methodologies\u003c\/p\u003e\n\n\u003cp\u003ePrimary Research Methodologies:\u003c\/p\u003e \n\n\u003cp\u003eQuestionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.\u003c\/p\u003e\n\n\u003cp\u003eSecondary Research Methodologies:\u003c\/p\u003e \n\n\u003cp\u003ePrintable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"October, 2023 \/ 303 Pages \/ MCW16238183","offer_id":47652851188018,"sku":null,"price":2628.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-point-of-care-testing-poct-market-by-diagnostics-segment-mode-platform-end-users-region-trends-recent-developments-company-profiles-forecast-to-2030","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}